(Q34633758)

3 August 2017

title

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. (English)

1 reference

multicenter clinical trial

3 August 2017

0 references

0 references

1 reference

1 reference

Øyvind Sverre Bruland

17

object named as

Oyvind S Bruland

1 reference

3 August 2017

Sten Nilsson

1

1 reference

3 August 2017

Lars Franzén

2

1 reference

3 August 2017

Christopher Parker

3

1 reference

3 August 2017

Christopher Tyrrell

4

1 reference

3 August 2017

René Blom

5

1 reference

3 August 2017

Jan Tennvall

6

1 reference

3 August 2017

Bo Lennernäs

7

1 reference

3 August 2017

Ulf Petersson

8

1 reference

3 August 2017

Dag C Johannessen

9

1 reference

3 August 2017

Michael Sokal

10

1 reference

3 August 2017

Katharine Pigott

11

1 reference

3 August 2017

Jeffrey Yachnin

12

1 reference

3 August 2017

Michael Garkavij

13

1 reference

3 August 2017

Peter Strang

14

1 reference

3 August 2017

Johan Harmenberg

15

1 reference

3 August 2017

Bjørg Bolstad

16

1 reference

3 August 2017

publication date

1 July 2007

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

587-594

1 reference

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970147-X

7 January 2021

10.1016/S1470-2045(07)70147-X

Identifiers

DOI

1 reference

3 August 2017

1 reference